August 19, 2018
August 19, 2018
Aug 19, 2018 – Lion TCR Pte. Ltd., a Singapore-based Biotech company receives approval from Health Sciences Authority (HSA), Singapore, for its Phase I/II multicentre clinical study of its product candidate (LioCyx™) for treatment of relapsed liver cancer post-liver transplantation. The first such trial in Singapore and for the region that uses precision T cell receptor (TCR) immune cell therapy to target Hepatitis B virus (HBV)-related liver cancer, which forms at least 80% of liver cancers in Asia. 80% of the 800,000 new liver cancer cases in the world yearly are diagnosed in Asia Pacific, including China, Vietnam, Thailand, Indonesia, South Korea and Singapore. Liver cancer is the world’s third most deadly cancer with very limited treatment options and poor treatment outcome. There is currently no effective treatment available for liver cancer relapsed patients post-liver transplantation.
LioCyx™ is developed by Lion TCR’s scientific founder, Prof. Antonio Bertoletti, a world-renowned HBV-liver cancer clinician scientist. Several Investigator-sponsored trials of LioCyx™ in Singapore and China have showed results of good safety profile and encouraging signs of efficacy. “We are very delighted with the approval of Phase I/II clinical trial of our LioCyx™, the first engineered TCR-T cell therapy for treatment of liver cancer in Singapore. It is an utmost encouragement on the recognition of innovative therapy for patients in need. Singapore HSA has been very efficient, transparent and professional in reviewing our application for the clinical trial of this innovative immunotherapy”, said Dr. Victor Li Lietao, founder and CEO of Lion TCR.
Patients recruitment for the Phase I/II clinical trial will begin with National University Hospital (NUH), Singapore. Lion TCR is in the midst of including more medical centres in Singapore and China into the trial.
About Lion TCR
Lion TCR is a Singapore-based clinical stage biotech company focusing on development of engineered T cell immunotherapy against viral-related cancer and chronic hepatitis B with manufacturing and clinical trial operations in China and Singapore. It is the first company in the world to develop HBV-specific TCR T cell therapy against liver cancer.
Lion TCR’s engineered T cell technologies are exclusively licensed from Agency for Science, Technology and Research (A*STAR), Singapore (TCR-T cell therapy developed by Prof. Antonio Bertoletti’s lab), and from Technical University of Munich (CAR-T cell therapy developed by Prof. Urlike Protzer’s lab).
Lion TCR has recently raised US$ 20 million new investments to advance the clinical trials of LioCyx™ in major hospitals in China and Singapore, as well as for broadening its products pipeline to fight viral-related solid tumours and clearance of chronic hepatitis B. PR Newswire
Lion TCR Announces Data Presentation for its lead T-cell product, LioCyx-M at EASL Digital Liver Cancer Summit 2021
HSA approval for Phase 1 IND clinical trial for Lion TCR’s lead product LioCyx-M to characterize changes in liver cancer tumor microenvironment
Lion TCR presents two abstracts of Phase 1 clinical trial data for lead product LioCyx-M at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Companion diagnostic assay for personalised immunotherapy for HBV-related liver cancer featured in A*STAR GIS website
Singapore’s first clinical trial approval for T cell engineered (TCR) immunotherapy for treatment of Liver cancer
Lion TCR receives US$ 20 million to fund its personalized T cell therapy clinical trials against Liver cancer
Scientific Founder, Prof. Antonio Bertoletti and Scientific Consultant, Dr Anthony Tanoto Tan of Lion TCR were awarded the SingHealth Duke-NUS Research Award 1st Prize 2018
US FDA grants Lion TCR two orphan drug designations of T cell therapy against Hepatocellular Carcinoma
New publication – Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient